JP2024523127A5 - - Google Patents

Info

Publication number
JP2024523127A5
JP2024523127A5 JP2023572104A JP2023572104A JP2024523127A5 JP 2024523127 A5 JP2024523127 A5 JP 2024523127A5 JP 2023572104 A JP2023572104 A JP 2023572104A JP 2023572104 A JP2023572104 A JP 2023572104A JP 2024523127 A5 JP2024523127 A5 JP 2024523127A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
drug
phosphatidylcholine
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523127A (ja
Filing date
Publication date
Priority claimed from CN202110558965.2A external-priority patent/CN115364218A/zh
Application filed filed Critical
Publication of JP2024523127A publication Critical patent/JP2024523127A/ja
Publication of JP2024523127A5 publication Critical patent/JP2024523127A5/ja
Pending legal-status Critical Current

Links

JP2023572104A 2021-05-21 2022-05-20 特定の薬剤脂質比を有する医薬組成物の抗腫瘍適用 Pending JP2024523127A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110558965.2A CN115364218A (zh) 2021-05-21 2021-05-21 一种特定药脂比的药物组合物在抗肿瘤中的应用
CN202110558965.2 2021-05-21
PCT/CN2022/094221 WO2022242762A1 (zh) 2021-05-21 2022-05-20 一种特定药脂比的药物组合物在抗肿瘤中的应用

Publications (2)

Publication Number Publication Date
JP2024523127A JP2024523127A (ja) 2024-06-28
JP2024523127A5 true JP2024523127A5 (https=) 2025-04-07

Family

ID=84059031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572104A Pending JP2024523127A (ja) 2021-05-21 2022-05-20 特定の薬剤脂質比を有する医薬組成物の抗腫瘍適用

Country Status (5)

Country Link
US (1) US20240216528A1 (https=)
EP (1) EP4353223A4 (https=)
JP (1) JP2024523127A (https=)
CN (1) CN115364218A (https=)
WO (1) WO2022242762A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116602923A (zh) * 2023-07-20 2023-08-18 暨南大学附属第一医院（广州华侨医院） 一种用于关节炎治疗的靶向仿生纳米治疗载体系统
CN120884711B (zh) * 2025-09-29 2025-12-26 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 一种逆转卵巢癌顺铂耐药的药物制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
NZ539901A (en) * 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection
WO2005021012A1 (ja) * 2003-08-29 2005-03-10 Terumo Kabushiki Kaisha ゲムシタビン封入薬剤担体
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
KR100889139B1 (ko) * 2004-06-01 2009-03-17 테루모 가부시키가이샤 이리노테칸 제제
JP4874097B2 (ja) * 2004-06-18 2012-02-08 テルモ株式会社 水難溶性カンプトテシン含有リポソーム製剤
CN101317820B (zh) * 2007-04-19 2012-02-29 中国人民解放军军事医学科学院毒物药物研究所 生物亲和性配体分子介导的靶向脂质体，其制 备及其应用
CN101264056A (zh) * 2008-04-22 2008-09-17 复旦大学 盐酸表阿霉素脂质体及其制备方法
CN110755611A (zh) * 2019-10-18 2020-02-07 中国药科大学 一种纳米簇载药热敏脂质体制剂及其制法和应用
CN112137958A (zh) * 2020-06-03 2020-12-29 上海舜纳生物科技有限公司 一种含阿霉素与免疫佐剂组合药物脂质体及其制备方法

Similar Documents

Publication Publication Date Title
Pillai Nanotechnology toward treating cancer: A comprehensive review
Palazzolo et al. The clinical translation of organic nanomaterials for cancer therapy: a focus on polymeric nanoparticles, micelles, liposomes and exosomes
Lu et al. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer
Zalba et al. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer
Pillai Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. SOJ Pharm Pharm Sci 1 (2): 13
Yi et al. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers
Yang et al. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells
O. Eloy et al. Rapamycin-loaded immunoliposomes functionalized with trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells
Blanco et al. Emerging nanotherapeutic strategies in breast cancer
EP2123260A1 (en) Liposome formulation and process for preparation thereof
US12370214B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
CN108348538B (zh) 包含吉西他滨脂质体组合物的肿瘤治疗药及试剂盒
US12370186B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and immune checkpoint inhibitor
JP2024523127A5 (https=)
Forouhari et al. Liposomes: Ideal drug delivery systems in breast cancer
CN112426535A (zh) 一种肿瘤靶向药物纳米晶递送系统
Serpico et al. Lipid nanoparticles-based RNA therapies for breast cancer treatment
EP4353223A1 (en) Application of pharmaceutical composition having specific drug-to-lipid ratio in antitumor
Bishal et al. Targeted Drug Delivery for Breast Cancer using Functionalized Liposomes: Preparation Methods, Challenges, and Clinical Translation
JP2024522316A5 (https=)
AU2016298606A1 (en) Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers
CN107510652B (zh) 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
AU2020364256A1 (en) Delivery system complexes comprising a precipitate of an active agent and methods of use
HK40108398A (en) Application of pharmaceutical composition having specific drug-to-lipid ratio in antitumor
Duarte Determination of the Activity of BNIPS Derivative Compounds Incorporated Into Liposomes Against Pancreatic Tumor Cells